☰

Karthik Bodhinathan, Ph.D. - Publications

Affiliations: 
Neuroscience TG Therapeutics 
Area:
Neurodegeneration, Memory, Neurophysiology, Synaptic Plasticity, Ion channels
Tree Info Grants Similar researchers PubMed Report error

15/20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Trudler D, Sanz-Blasco S, Eisele YS, Ghatak S, Bodhinathan K, Akhtar MW, Lynch WP, Piña-Crespo JC, Talantova M, Kelly JW, Lipton SA. α-Synuclein Oligomers Induce Glutamate Release from Astrocytes and Excessive Extrasynaptic NMDAR Activity in Neurons, Thus Contributing to Synapse Loss. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 33483428 DOI: 10.1523/JNEUROSCI.1871-20.2020  0.396
2017 Lacin E, Aryal P, Glaaser IW, Bodhinathan K, Tsai E, Marsh N, Tucker SJ, Sansom MSP, Slesinger PA. Dynamic role of the tether helix in PIP2-dependent gating of a G protein-gated potassium channel. The Journal of General Physiology. PMID 28720589 DOI: 10.1085/Jgp.201711801  0.697
2016 Takahashi H, Xia P, Cui J, Talantova M, Bodhinathan K, Li W, Saleem S, Holland EA, Tong G, Piña-Crespo J, Zhang D, Nakanishi N, Larrick JW, McKercher SR, Nakamura T, et al. Corrigendum: Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease. Scientific Reports. 6: 20750. PMID 26867695 DOI: 10.1038/srep20750  0.424
2015 Takahashi H, Xia P, Cui J, Talantova M, Bodhinathan K, Li W, Holland EA, Tong G, Piña-Crespo J, Zhang D, Nakanishi N, Larrick JW, McKercher SR, Nakamura T, Wang Y, et al. Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease. Scientific Reports. 5: 14781. PMID 26477507 DOI: 10.1038/srep14781  0.502
2014 Bodhinathan K, Slesinger PA. Alcohol modulation of G-protein-gated inwardly rectifying potassium channels: from binding to therapeutics. Frontiers in Physiology. 5: 76. PMID 24611054 DOI: 10.3389/Fphys.2014.00076  0.631
2013 Bodhinathan K, Slesinger PA. Molecular mechanism underlying ethanol activation of G-protein-gated inwardly rectifying potassium channels. Proceedings of the National Academy of Sciences of the United States of America. 110: 18309-14. PMID 24145411 DOI: 10.1073/Pnas.1311406110  0.631
2013 Balana B, Bahima L, Bodhinathan K, Taura JJ, Taylor NM, Nettleton MY, Ciruela F, Slesinger PA. Ras-association domain of sorting Nexin 27 is critical for regulating expression of GIRK potassium channels. Plos One. 8: e59800. PMID 23536889 DOI: 10.1371/Journal.Pone.0059800  0.705
2013 Bodhinathan K, Slesinger PA. Dissecting Gating Rules of GIRK Channels: Role of PIP2 in Ethanol-Dependent Activation Biophysical Journal. 104: 130a. DOI: 10.1016/J.Bpj.2012.11.744  0.645
2012 Wu K, Li S, Bodhinathan K, Meyers C, Chen W, Campbell-Thompson M, McIntyre L, Foster TC, Muzyczka N, Kumar A. Enhanced expression of Pctk1, Tcf12 and Ccnd1 in hippocampus of rats: Impact on cognitive function, synaptic plasticity and pathology. Neurobiology of Learning and Memory. 97: 69-80. PMID 21982980 DOI: 10.1016/J.Nlm.2011.09.006  0.49
2012 Bodhinathan K, Slesinger PA. Engineering the Alcohol Pocket to Create a Chemically-Activated GIRK Channel Biophysical Journal. 102: 537a. DOI: 10.1016/J.Bpj.2011.11.2937  0.631
2012 Balana B, Bahima L, Bodhinathan K, Taylor NM, Nettleton MY, Ciruela F, Slesinger PA. Ras-Associated (RA) Domain of Sorting Nexin 27 (SNX27) is Critical for Regulating GIRK Channels Biophysical Journal. 102: 537a. DOI: 10.1016/J.Bpj.2011.11.2936  0.696
2010 Bodhinathan K, Kumar A, Foster TC. Redox sensitive calcium stores underlie enhanced after hyperpolarization of aged neurons: role for ryanodine receptor mediated calcium signaling. Journal of Neurophysiology. 104: 2586-93. PMID 20884759 DOI: 10.1152/Jn.00577.2010  0.546
2010 Bodhinathan K, Kumar A, Foster TC. Intracellular redox state alters NMDA receptor response during aging through Ca2+/calmodulin-dependent protein kinase II. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 1914-24. PMID 20130200 DOI: 10.1523/Jneurosci.5485-09.2010  0.528
2009 Kumar A, Bodhinathan K, Foster TC. Susceptibility to Calcium Dysregulation during Brain Aging. Frontiers in Aging Neuroscience. 1: 2. PMID 20552053 DOI: 10.3389/Neuro.24.002.2009  0.513
2009 Zeier Z, Kumar A, Bodhinathan K, Feller JA, Foster TC, Bloom DC. Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome. Gene Therapy. 16: 1122-9. PMID 19571888 DOI: 10.1038/Gt.2009.83  0.5
Low-probability matches (unlikely to be authored by this person)
2006 Dhar D, Mapa K, Pudi R, Srinivasan P, Bodhinathan K, Das S. Human ribosomal protein L18a interacts with hepatitis C virus internal ribosome entry site. Archives of Virology. 151: 509-24. PMID 16195786 DOI: 10.1007/s00705-005-0642-6  0.228
2024 Nakamura K, Sun Z, Hara-Cleaver C, Bodhinathan K, Avila RL. Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial. Multiple Sclerosis (Houndmills, Basingstoke, England). 13524585241235055. PMID 38469809 DOI: 10.1177/13524585241235055  0.05
2024 Butzkueven H, Kalincik T, Patti F, Slee M, Weinstock-Guttman B, Buzzard K, Skibina O, Alroughani R, Prat A, Girard M, Horakova D, Havrdova EK, Van der Walt A, Eichau S, Hyde R, ... ... Bodhinathan K, et al. Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies. Therapeutic Advances in Neurological Disorders. 17: 17562864231221331. PMID 38414723 DOI: 10.1177/17562864231221331  0.032
2022 Foley J, Berkovich R, Gudesblatt M, Luce E, Schneider B, de Moor C, Liao S, Lee L, Bodhinathan K, Avila R. Characterizing the 'feel-good experience' in multiple sclerosis patients treated with natalizumab or other therapies. Neurodegenerative Disease Management. PMID 36285716 DOI: 10.2217/nmt-2022-0003  0.029
2023 Ryerson LZ, Foley JF, Defer G, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Sinks S, Kuhelj R, Bodhinathan K, Lasky T. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders. 72: 104561. PMID 36931078 DOI: 10.1016/j.msard.2023.104561  0.025
Hide low-probability matches.